Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis

Ambulatory Pediatrics

Volumn 2, Issue 6, 2002, Pages 444-448

  Robbins, James M ^a   Tilford, John M ^a   Gillaspy, Stephen R ^a   Shaw, Jennifer L ^a   Simpson, Donald D ^a   Jacobs, Richard F ^a   Wheeler, Gary J ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Bronchiolitis; Economic analysis; Family impact; Respiratory syncytial virus; Time costs; Treatment adherence

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG INFUSION; ECONOMIC EVALUATION; EMOTIONAL STRESS; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; PARENTAL BEHAVIOR; PATIENT ATTITUDE; PATIENT COMPLIANCE; PEDIATRIC HOSPITAL; PREDICTION; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TIME; UNITED STATES;

EID: 0036862960     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1367/1539-4409(2002)002<0444:PEATCP>2.0.CO;2     Document Type: Article

References (22)

1. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York, NY. Churchill Livingstone Publishers; 1995.
2. The Prevent Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
3. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
4. Seid M, Kurtin PS, Romanowski GL, et al. Effectiveness of RSV-IG in premature infants: potential pitfalls in clinical settings [letter]. Pediatrics. 1998;101:320-321.
5. Kazak AE, Boyer BA, Brophy P, et al. Parental perceptions of procedure-related distress and family adaptation in childhood leukemia. Child Health Care. 1995;24:143-158.
6. Kazak AE, Penati B, Waibel MK, Blackall GF. The Perception of Procedures Questionnaire: psychometric properties of a brief parent report measure of procedural distress. J Pediatr Psychol. 1996;21:195-207.
7. Fuller B, Thomson M, Conner DA, Scanlan J. Relationship of cues to assessed infant pain level. Clin Nurs Res. 1996;5:43-66.
8. Bauchner H, Vinci R, Bak S, et al. Parents and procedures: a randomized controlled trial. Pediatrics. 1996;98:861-867.
9. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:176-213.
10. American Academy of Pediatrics, Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216.
11. Simoes EAF, Groothuis JRT, Tristam DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129:214-219.
12. American Academy of Pediatrics, Committee on Infectious Disease and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997;99:645-650.
13. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr Pulmonol. 2001; 32:20-28.
14. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care. 1996;2:851-861.
15. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-427.
16. Meissner HC, Welliver RC, Chartrand SA, et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J. 1996;15:1059-1068.
17. Moler FW, Brown RW, Faix RG, Gilsdorf JR. Comments on palivizumab (Synagis). Pediatrics. 1999;103:495-497.
18. O'Shea TM, Sevick MA, Givner LB. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J. 1998;17:587-593.
19. Robbins JM, Tilford JM, Jacobs RF, et al. A number needed to treat analysis of RSV-IG for the prevention of hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366.
20. Sanchez PJ. Immunoprophylaxis of respiratory syncytial virus disease. Pediatr Infect Dis J. 2000;19:791-801.
21. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
22. Veerman M, Reuman P, Burchfield D, Sherman J. Cost-effectiveness of RespiGam in a university teaching hospital [letter]. Pediatrics. 1997;100:160.